Vernalis is a new force in UK biotechnology formed out of the September 2003 merger of British Biotech plc and Vernalis Group plc. This merger has created a company with significant growth potential, through sales of its marketed product, frovatriptan, the successful development and commercialisation of its product pipeline candidates, and through further participation in the consolidation of the UK biotechnology sector. 
The Company’s most advanced product, frovatriptan, has received regulatory approval in the US and in 15 European countries for the acute treatment of migraine. Further studies are under way to develop the product as an oral prophylactic for menstrual-associated migraine, a condition thought to affect as many as half of the 15%-20% of all women who suffer from migraine.
Supporting frovatriptan are a range of clinical and pre-clinical development programmes targeting large potential markets - principally thrombotic diseases, pain and Parkinson's disease.
This pipeline is supplied by research programmes exploiting our distinctive structure based drug discovery and CNS biology capabilities, investigating the potential of a variety of novel molecules and targets in the fields of oncology, obesity, inflammation and depression.